SEARCH

SEARCH BY CITATION

References

  • 1
    Israeli RS, Ryan CW, Jung LL. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol. 2008; 179: 41423.
  • 2
    Smith MR. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res. 2006; 12: 6315s9s.
  • 3
    Bauer DC, Garnero P, Harrison SL, Cauley JA, Eastell R, Ensrud KE, Orwoll E; Osteoporotic Fractures in Men (MrOS) Research Group. Biochemical markers of bone turnover, hip bone loss and fracture in older men: the MrOS Study. J Bone Miner Res. 2009; 24(12): 20328.
  • 4
    Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int. 2009; 20: 84351.
  • 5
    Mariela V, Alonso G, Flores SQ, Rozas-Moreno P, Gonalez-Ramirez AR, Mijan Ortiz JL, Jodar E, Munoz-Torres M. Relationships between sex steroids and markers of bone turnover in prostate cancer males with and without androgen deprivation therapy. ASBMR 31st Annual Meeting, Denver, CO, USA, 2009. J Bone Miner Res. 24 (Suppl 1): Available from: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=f26d8e30-ff52-4a1c-b9f9-ce4a0daf4ed3. Accessed September 18, 2011.
  • 6
    Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab. 2003; 88: 20410.
  • 7
    Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, Tran DNH, Warsi GM, Lacerna LV. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer. 2007; 5: 2717.
  • 8
    Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S, Resnick NM. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol. 2008; 27: 442634.
  • 9
    Body JJ, Lipton A, Gralow J, Steger GG, Gao G, Yeh H, Fizazi K. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res. 2010; 25: 4406.
  • 10
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361: 75665.
  • 11
    Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee A-I, Zheng M, Hei Y-J, Coleman RE. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005; 97: 5969.
  • 12
    Saad F, Eastham JA, Smith MR. Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. Urol Oncol. 2010 Dec 15. [Epub ahead of print] [http://dx.doi.org/10.1016/j.urolonc.2010.08.007].
  • 13
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005; 352: 15464.
  • 14
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998; 13: 14318.
  • 15
    Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009; 361: 74555.
  • 16
    van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst. 1960; 37: 35161.
  • 17
    Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008; 43: 2229.
  • 18
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003; 169: 200812.
  • 19
    Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001; 345: 94855.
  • 20
    Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998; 19: 80100.
  • 21
    Bekker PJ, Holloway DI, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004; 19: 105966.